Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -97.64% | 882.87% | 638.83% | 577.05% | 485.75% |
| Total Depreciation and Amortization | 44.19% | 14.90% | -21.40% | 5.26% | -42.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.17% | -2,959.54% | -2,179.76% | -1,770.12% | -1,424.46% |
| Change in Net Operating Assets | -403.35% | -33.88% | -431.01% | 49.33% | -203.26% |
| Cash from Operations | 39.16% | 39.66% | 15.82% | 9.26% | -2.97% |
| Capital Expenditure | -314.38% | -83.21% | 58.40% | 90.00% | 95.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -97.06% | 169,384.76% | 78,128.51% | 78,128.51% | 77,689.27% |
| Other Investing Activities | 60,834.06% | 1,255.87% | 105.79% | 106.13% | 100.36% |
| Cash from Investing | -91.34% | 7,008.94% | 14,273.96% | 11,854.55% | 3,347.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -278.70% | -12.64% | 23.99% | -4.65% | 30.03% |
| Issuance of Common Stock | 13.82% | -87.27% | -87.27% | -64.78% | -69.47% |
| Repurchase of Common Stock | -10,298.05% | -10,007.72% | -10,007.72% | -298.96% | 4.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 252.49% | 252.49% | 264.61% | 273.67% |
| Cash from Financing | -245.88% | -178.70% | -168.15% | -16.04% | 128.23% |
| Foreign Exchange rate Adjustments | -259.38% | -372.65% | -372.65% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.81% | 2,353.86% | 937.31% | 1,372.09% | 850.90% |
